Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: An open-label evaluation

Psychopharmacology

Volumn 198, Issue 2, 2008, Pages 149-158

  Lanier, Ryan K ^a   Umbricht, Annie ^a   Harrison, Joseph A ^a   Nuwayser, Elie S ^b   Bigelow, George E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOTEK Inc   (United States)

Author keywords

Buprenorphine; Dependence; Detoxification; Opioid; Patch; Transdermal; Withdrawal

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; OPIATE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; DETOXIFICATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MEDICAL RESEARCH; OPEN STUDY; PRIORITY JOURNAL; SELF REPORT; TRANSDERMAL PATCH; VITAL SIGN;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; BUPRENORPHINE; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 43049136817     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1105-z     Document Type: Article

References (32)

1. Amass L, Bickel WK, Higgins ST, Hughes JR (1994) A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 13:33-45
2. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T (2004) Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 13(Suppl 1):S42-S66
3. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA (2004) Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 73:219-226
4. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988a) A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78
5. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988b) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247:47-53
6. Brigham GS, Amass L, Winhusen T, Harrer JM, Pelt A (2007) Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat 32:349-356
7. Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J (1999) Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 55:157-163
8. Cheskin LJ, Fudala PJ, Johnson RE (1994) A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 36:115-121
9. Chiang CN, Hawks RL (2003) Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 70:S39-S47
10. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML (2002) High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) 161:202-212
11. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496-1509
12. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459
13. Gowing L, Ali R, White J (2006) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev: CD002025
14. Himmelsbach CK (1941) The morphine abstinence syndrome, its nature and treatment. Ann Intern Med 15:829-839
15. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E (1994) Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 36:139-145
16. Kleber HD, Riordan CE (1982) The treatment of narcotic withdrawal: a historical review. J Clin Psychiatry 43:30-34
17. Kosten TR, Kleber HD (1988) Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 42:635-641
18. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20:369-378
19. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ (1998) Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 93:549-559
20. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE (2007) Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction 102:1648-1656
21. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100:1090-1100
22. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L (2002) A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97:1395-1404
23. Lintzeris N, Bammer G, Rushworth L, Jolley DJ, Whelan G (2003) Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study. Drug Alcohol Depend 70:287-294
24. Mattick RP, Hall W (1996) Are detoxification programmes effective? Lancet 347:97-100
25. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL (2002) A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 306:31-39
26. Nigam AK, Ray R, Tripathi BM (1993) Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 10:391-394
27. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ (1997) Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 127:526-530
28. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC (2005) A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77:71-79
29. Schuh KJ, Johanson CE (1999) Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56:55-60
30. Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-432
31. Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE (2004) Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 73:11-22
32. Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37-43